| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 08/22/2013 | WO2013120629A1 Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein |
| 08/22/2013 | WO2013120628A1 Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen |
| 08/22/2013 | WO2013120627A1 Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen |
| 08/22/2013 | WO2013120626A1 Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen |
| 08/22/2013 | WO2013120554A1 Antibodies that bind peptidoglycan recognition protein 1 |
| 08/22/2013 | WO2013120498A1 Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen |
| 08/22/2013 | WO2013120497A1 Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein |
| 08/22/2013 | WO2013096380A3 Anti-phf-tau antibodies and their uses |
| 08/22/2013 | WO2013093919A8 A combination therapy for a stable and long term engraftment using specific protocols for t/b cell depletion |
| 08/22/2013 | WO2013090633A3 Composition and method for the diagnosis and treatment of iron-related disorders |
| 08/22/2013 | WO2013076580A3 Recombinant proteins and their therapeutic uses |
| 08/22/2013 | WO2013075027A3 Anti-sil6xr complex binding domains and methods of use |
| 08/22/2013 | WO2013072768A3 Synthetic derivatives of mpl and uses thereof |
| 08/22/2013 | WO2013064830A3 Medical use |
| 08/22/2013 | WO2005007218A3 Ex vivo perfusion |
| 08/22/2013 | US20130219534 Methods for the Treatment and Prevention of Metabolic Disorders |
| 08/22/2013 | US20130217865 Tumor Specific Antibody |
| 08/22/2013 | US20130217857 Erbb interface peptidomimetics and methods of use thereof |
| 08/22/2013 | US20130217116 Peptide II |
| 08/22/2013 | US20130217048 Immunizing Compositions and Methods of Use |
| 08/22/2013 | US20130216621 Bifunctional conjugate compositions and associated methods |
| 08/22/2013 | US20130216613 Cytomegalovirus gb antigen |
| 08/22/2013 | US20130216608 Airway Administration of Angiogenesis Inhibitors |
| 08/22/2013 | US20130216591 Composition and method for inducing antigen-specific tolerance using IgA |
| 08/22/2013 | US20130216589 Oral vaccine for aquatic animals |
| 08/22/2013 | US20130216583 Vaccine composition comprising an antigen and a peptide having adjuvant properties |
| 08/22/2013 | US20130216582 Suppression of a type 1 hypersensitivity immune response with an unrelated antigen |
| 08/22/2013 | US20130216581 Carbon Nanotube Compositions and Methods of Use Thereof |
| 08/22/2013 | US20130216580 Heterologous prime boost vaccination regimen against malaria |
| 08/22/2013 | US20130216578 Recombinant trypanosoma theileri parasite |
| 08/22/2013 | US20130216576 Pneumococcal serotype 6d |
| 08/22/2013 | US20130216575 Recombinant subunit dengue virus vaccine |
| 08/22/2013 | US20130216574 Kit providing multiple unmet therapeutic effects |
| 08/22/2013 | US20130216573 Influenza virus reassortment |
| 08/22/2013 | US20130216572 Immediate protection against pathogens via mva |
| 08/22/2013 | US20130216571 Multivalent Meningococcal Polysaccharide-Protein Conjugate Vaccine |
| 08/22/2013 | US20130216569 Vaccine |
| 08/22/2013 | US20130216568 Immunogenic proteins and compositions |
| 08/22/2013 | US20130216566 Vectors expressing SARS immunogens, compositions containing such vectors or expression products thereof, methods and assays for making and using |
| 08/22/2013 | US20130216565 Vaccines based on peptides of the complement protein c5a |
| 08/22/2013 | US20130216564 Immunogenic Epitopes, Peptidomimetics, And Anti-Peptide Antibodies, And Methods of Their Use |
| 08/22/2013 | US20130216558 Compositions and methods for treating haematological proliferative disorders of myeloid origin |
| 08/22/2013 | US20130216556 Antibody formulations |
| 08/22/2013 | US20130216554 Methods for Producing Enteroendocrine Cells That Make and Secrete Insulin |
| 08/22/2013 | US20130216553 Compositions and Methods for Modulation and Detection of Immune and Inflammatory Responses |
| 08/22/2013 | US20130216550 Breast cancer therapeutics |
| 08/22/2013 | US20130216548 Monoclonal antibodies against c-met |
| 08/22/2013 | US20130216546 Methods of Treating Glucose Metabolism Disorders |
| 08/22/2013 | US20130216545 Early Diagnosis and Novel Treatment of Cancer |
| 08/22/2013 | US20130216540 Modulation of the innate immune system through the trem-like transcript 2 protein |
| 08/22/2013 | US20130216536 Inhibitors of extracellular hsp90 |
| 08/22/2013 | US20130216534 Use of il-20 antagonists for treating rheumatoid arthritis and osteoporosis |
| 08/22/2013 | US20130216533 Biological markers for identifying patients for treatment with vegf antagonists |
| 08/22/2013 | US20130216531 Anti-cxcr4 as a sensitizer to cancer therapeutics |
| 08/22/2013 | US20130216530 Methods for optimizing biological response modifier therapy using therapeutic drug monitoring of immunosuppressants |
| 08/22/2013 | US20130216527 Novel anti-cmet antibody |
| 08/22/2013 | US20130216526 Methods for reducing viral load in hiv-1 infected patients |
| 08/22/2013 | US20130216525 Concentrated protein formulations and uses thereof |
| 08/22/2013 | US20130216524 Predictors for Cancer Treatment |
| 08/22/2013 | US20130216523 Methods for Facilitating Diagnosis, Prognosis and Treatment of Cancer by Detecting HER1 Expression |
| 08/22/2013 | US20130216522 Stabilized human immunoglobulin composition |
| 08/22/2013 | US20130216521 Dietary supplement for enhancing animal health |
| 08/22/2013 | US20130216509 Chimeric receptors with 4-1bb stimulatory signaling domain |
| 08/22/2013 | US20130216496 Methods for treating tweak-related conditions |
| 08/22/2013 | US20130216476 Use of an anti-cd71 antibody for preparing a medicament |
| 08/22/2013 | CA2857560A1 Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen |
| 08/22/2013 | CA2856891A1 Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen |
| 08/21/2013 | EP2628752A1 Engineered anti-TSLP antibody |
| 08/21/2013 | EP2628751A2 Binding members for interleukin-6 and use thereof |
| 08/21/2013 | EP2628750A2 Targeted identification of immunogenic peptides |
| 08/21/2013 | EP2628486A2 Method for treating bone fracture with anti-sclerostin antibodies |
| 08/21/2013 | EP2627673A1 Therapies for improving pulmonary function |
| 08/21/2013 | EP2627357A2 Antibodies that bind amyloid oligomers |
| 08/21/2013 | EP2627356A2 Human oncostatin m antibodies and methods of use |
| 08/21/2013 | EP2627355A1 Suppression of a hypersensitivity immune response with unrelated antigen derived from allergen source material |
| 08/21/2013 | EP2627354A1 Suppression of a type 1 hypersensitivity immune response with an unrelated antigen |
| 08/21/2013 | EP2627353A1 Norovirus capsid and rotavirus vp6 protein for use as combined vaccine |
| 08/21/2013 | EP2627352A2 Novel antigen |
| 08/21/2013 | EP2627351A2 Antigen delivery platforms |
| 08/21/2013 | EP2627340A1 A method of regulating plasma lipoproteins |
| 08/21/2013 | EP2627198A1 Immunoadjuvant |
| 08/21/2013 | EP2143437B1 Compositions and methods for the diagnosis and treatment of tumor |
| 08/21/2013 | EP1516628B1 Stable isotonic lyophilized protein formulation |
| 08/21/2013 | CN1909922B Novel flavivirus antigens |
| 08/21/2013 | CN103261412A Antihuman CCR7 antibodies, hybridoma, nucleic acid, vector, cell, medicinal composition, and antibody-mmobilized carrier |
| 08/21/2013 | CN103261230A Anti-PCSK9 antibodies and methods of use |
| 08/21/2013 | CN103261227A CD33 binding agents |
| 08/21/2013 | CN103261223A Human oncostatin M antibodies and methods of use |
| 08/21/2013 | CN103261214A Vaccines with live bacterial isolates for systemic administration |
| 08/21/2013 | CN103260647A EGFR antagonist for the treatment of heart disease |
| 08/21/2013 | CN103260646A Notum protein modulators and methods of use |
| 08/21/2013 | CN103260645A Norovirus capsid and rotavirus vp6 protein for use as combined vaccine |
| 08/21/2013 | CN103260644A Parapoxvirus vectors containing rabies virus antigen |
| 08/21/2013 | CN103260643A Recombinant ndv antigen and uses thereof |
| 08/21/2013 | CN103260642A Mycobacterium antigenic composition |
| 08/21/2013 | CN103260641A Treatment and prevention of malaria |
| 08/21/2013 | CN103260640A Active protease-resistant antibody Fc mutants |
| 08/21/2013 | CN103260639A Dual variable domain immunoglobulins and uses thereof |
| 08/21/2013 | CN103260638A Immunoglobulin cleavage fragments vaccine compositions |
| 08/21/2013 | CN103257236A Application of specific CTL cell epitope peptide of HLA-A24 restrictive Mycobacterium tuberculosis |